SCHEMBL3015047

SCHEMBL3015047

COc1ccc(-c2csc(N3CCN(S(=O)(=O)c4ccccc4C(F)(F)F)CC3)n2)c(OC)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.51
USP2 O75604 2/20 0.51
RECQL P46063 1/20 0.51
HSD17B10 Q99714 1/20 0.51
KMT2A Q03164 6/20 0.47
MEN1 O00255 4/20 0.47
AR P10275 1/20 0.46
LMNA P02545 4/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
ALDH1A1 P00352 3/20 0.45
REV1 Q9UBZ9 1/20 0.45
KCNQ1 P51787 1/20 0.44
RAB9A P51151 2/20 0.44
NPC1 O15118 1/20 0.44
NFKB1 P19838 1/20 0.44
NFKB2 Q00653 1/20 0.44
RELA Q04206 1/20 0.44
ATM Q13315 1/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
KDM4E B2RXH2 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3649820 0.97 REV1 (0.50) MAPTUSP2RECQLHSD17B10KMT2A
SCHEMBL3018032 0.93 REV1 (0.53) MAPTUSP2RECQLHSD17B10KMT2A
SCHEMBL3017437 0.90 KMT2A (0.51) MAPTUSP2RECQLHSD17B10KMT2A
SCHEMBL3011256 0.88 MAPT (0.51) MAPTUSP2RECQLHSD17B10KMT2A
SCHEMBL3012956 0.87 MAPT (0.51) MAPTUSP2RECQLHSD17B10KMT2A
SCHEMBL3007753 0.87 MAPT (0.58) MAPTUSP2RECQLHSD17B10KMT2A
SCHEMBL3009895 0.86 AR (0.47) MAPTUSP2RECQLHSD17B10KMT2A
SCHEMBL3011444 0.86 MAPT (0.53) MAPTUSP2RECQLHSD17B10KMT2A
SCHEMBL3019418 0.86 MAPT (0.69) MAPTUSP2RECQLHSD17B10KMT2A
SCHEMBL3006291 0.86 MAPT (0.58) MAPTUSP2RECQLHSD17B10KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885USP2 1831/4885RECQL 1564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.